This time last year, the chairman and chief executive officer of Israel’s Teva Pharmaceutical Industries Ltd., the world’s biggest generic drugmaker, were foreigners. Miami billionaire Phillip Frost led the board and Jeremy Levin, a South African, was CEO. They were the first non- Israelis to hold those positions.
The White House may have difficulty bolstering U.S. cyber defenses through an executive order unless there’s enough public support, according to former National Security Agency director Michael Hayden.
Teva Pharmaceutical Industries Ltd. failed to win backing from the European Union drug regulator for a new pill to treat multiple sclerosis, hurting the company’s effort to introduce a successor to its best-selling injection Copaxone.
Huawei Technologies Co., China’s largest maker of telecommunications equipment, denied that it poses a security threat after the former director of the U.S. Central Intelligence Agency said it spies for China.
U.S. President Barack Obama’s call for more oversight and transparency in the National Security Agency’s surveillance programs shows that he wants to make Americans “more comfortable” with the agency’s operations, former NSA director Michael Hayden said.
Leaked information on U.S. government surveillance programs has “punished American business,” which has complied with court orders, said Michael Hayden, former director of the National Security Agency and the Central Intelligence Agency.
Teva Pharmaceutical Industries Ltd.’s plan to reformulate or repurpose existing drugs will generate $3 billion of sales by 2020, part of a strategy to counter a decline in revenue from its best-selling Copaxone multiple sclerosis treatment.
The disclosure of National Security Agency secrets by 29-year-old computer systems technician Edward Snowden is drawing new scrutiny of security processes and U.S. intelligence agencies’ reliance on contractors such as Snowden’s employer, Booz Allen Hamilton Holding Corp.
Teva Pharmaceutical Industries Ltd. rose to a one-year high after the maker of generic medicines said it plans to return to a deal-making strategy that made it one of the most acquisitive drug companies of the past decade.